This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, bringing readers up to date with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.
Arvustused
This is a small but comprehensive book that focuses on the molecular pathophysiology of asthma, and discusses different targeted biological therapies, including several drugs targeting multiple pathways that are currently in development. It would be a welcome acquisition for pulmonologists, immunologists, or any physicians with an interest in this topic. (Santosh Dhungana, Doodys Book Reviews, April, 2017)
|
|
|
1 | (4) |
|
|
|
3 | (2) |
|
2 Inflammatory Cellular Patterns in Asthma |
|
|
5 | (12) |
|
|
|
5 | (3) |
|
|
|
8 | (2) |
|
Mixed Granulocytic (Eosinophilic/Neutrophilic) Airway Inflammation |
|
|
10 | (1) |
|
|
|
11 | (1) |
|
|
|
11 | (1) |
|
|
|
12 | (5) |
|
3 Airway Remodelling in Asthma |
|
|
17 | (10) |
|
|
|
17 | (2) |
|
|
|
19 | (1) |
|
Airway Smooth Muscle Remodelling |
|
|
20 | (1) |
|
Increased Bronchial Vasculature |
|
|
21 | (1) |
|
|
|
22 | (1) |
|
|
|
22 | (5) |
|
|
|
27 | (24) |
|
Role of IgE in Allergic Asthma |
|
|
27 | (4) |
|
Omalizumab: Mechanism of Action and Pharmacokinetics |
|
|
31 | (2) |
|
Therapeutic Use of Omalizumab as Add-On Treatment for Asthma |
|
|
33 | (6) |
|
Safety and Tolerability Profile of Omalizumab |
|
|
39 | (1) |
|
Cost-Effectiveness of Omalizumab Treatment for Severe Asthma |
|
|
40 | (1) |
|
Future Perspectives of Anti-IgE Therapy |
|
|
41 | (1) |
|
|
|
42 | (1) |
|
|
|
43 | (8) |
|
5 IL-5-Targeted Antibodies |
|
|
51 | (16) |
|
Role of IL-5 in Eosinophilic Asthma |
|
|
51 | (2) |
|
|
|
53 | (3) |
|
|
|
56 | (3) |
|
|
|
59 | (3) |
|
|
|
62 | (1) |
|
|
|
63 | (4) |
|
6 Anti-IL-4/IL-13 Biologies |
|
|
67 | (16) |
|
Role of IL-4 and IL-13 in Asthma Pathobiology |
|
|
67 | (2) |
|
IL-4-/IL-13-Targeted Therapies |
|
|
69 | (10) |
|
|
|
69 | (3) |
|
|
|
72 | (1) |
|
|
|
72 | (3) |
|
Anti-IL-4/IL-13 Bispecific Antibodies |
|
|
75 | (1) |
|
|
|
75 | (2) |
|
|
|
77 | (1) |
|
|
|
78 | (1) |
|
|
|
79 | (1) |
|
|
|
79 | (4) |
|
|
|
83 | (6) |
|
|
|
86 | (3) |
|
8 Biologic Treatments Targeted to Innate Cytokines |
|
|
89 | (4) |
|
Anti-IL-25 Monoclonal Antibodies |
|
|
89 | (1) |
|
|
|
89 | (1) |
|
|
|
90 | (1) |
|
|
|
90 | (3) |
|
|
|
93 | (4) |
|
Anti-IL-9 Monoclonal Antibodies |
|
|
93 | (1) |
|
|
|
94 | (1) |
|
Anti-IL-17 and Anti-IL-23 Therapies |
|
|
94 | (1) |
|
|
|
95 | (2) |
|
10 Conclusions and Future Perspectives |
|
|
97 | |
|
|
|
98 | |
Girolamo Pelaia is Full Professor of Respiratory Medicine at the University Magna Graecia of Catanzaro, Italy. In 1985 he received his degree in Medicine and Surgery from the University of Reggio Calabria, Italy, and in 1989 he graduated as Specialist in Respiratory Diseases at the University of Naples Federico II, Italy. From 1990 to 1992 he was Post-Doctoral Fellow at the School of Medicine of Georgetown University, Washington, D.C., USA. Prof. Pelaias research activity and scientific production primarily deal with the pathophysiology and clinical pharmacology of chronic respiratory disorders such as asthma and COPD. He has authored or co-authored over 150 original articles and reviews published in both national and international journals, and several book chapters.
Alessandro Vatrella is Associate Professor of Respiratory Medicine at the University of Salerno, Italy. In 1982 he received his degree in Medicine and Surgery from the University of Naples Federico II,Italy, where in 1986 he also graduated as Specialist in Respiratory Diseases. Prof. Vatrellas research activity and scientific production primarily deal with the pharmacological modulation of bronchoconstriction and airway inflammation. In particular, he studied the basic mechanisms of airway hyper-responsiveness using experimental mo
dels of asthma induced by different stimuli such as methacholine, ultrasonic nebulized distilled water and beta-blocking drugs. He has authored or co-authored over 200 original articles and reviews published in both national and international journals, and several book chapters. Rosario Maselli is Full Professor of Respiratory Medicine at the University Magna Graecia of Catanzaro, Italy. In 1973 he received his degree in Medicine and Surgery from the University of Naples Federico II, Italy, where in 1976 he also graduated as Specialist in Respiratory Diseases. Prof. Masellis early research activity primarily focused on the utilization ofmass spectrometry, which was used to obtain information about lung volumes and cardiac output. His group is currently studying the involvement, in both respiratory pathophysiology and pulmonary pharmacology, of the signaling mechanisms mediated by mitogen-activated protein kinases. He has authored or co-authored over 150 original articles and reviews published in both national and international journals, and several book chapters.
